JP2008505636A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505636A5
JP2008505636A5 JP2007520225A JP2007520225A JP2008505636A5 JP 2008505636 A5 JP2008505636 A5 JP 2008505636A5 JP 2007520225 A JP2007520225 A JP 2007520225A JP 2007520225 A JP2007520225 A JP 2007520225A JP 2008505636 A5 JP2008505636 A5 JP 2008505636A5
Authority
JP
Japan
Prior art keywords
seq
nos
sequences
cloning
primer sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007520225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2005/002111 external-priority patent/WO2006004362A1/en
Publication of JP2008505636A publication Critical patent/JP2008505636A/ja
Publication of JP2008505636A5 publication Critical patent/JP2008505636A5/ja
Pending legal-status Critical Current

Links

JP2007520225A 2004-07-03 2005-07-04 Hcvに有効なctl反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 Pending JP2008505636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040051782 2004-07-03
PCT/KR2005/002111 WO2006004362A1 (en) 2004-07-03 2005-07-04 Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof

Publications (2)

Publication Number Publication Date
JP2008505636A JP2008505636A (ja) 2008-02-28
JP2008505636A5 true JP2008505636A5 (enExample) 2008-07-31

Family

ID=35783125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007520225A Pending JP2008505636A (ja) 2004-07-03 2005-07-04 Hcvに有効なctl反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途

Country Status (6)

Country Link
US (1) US20080112977A1 (enExample)
EP (1) EP1778719A1 (enExample)
JP (1) JP2008505636A (enExample)
KR (1) KR100790646B1 (enExample)
CN (1) CN1976946A (enExample)
WO (1) WO2006004362A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ctl 유도제 조성물
CN102174522B (zh) * 2011-02-24 2013-11-06 杭州师范大学 一种4-1bbl蛋白的制备方法
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
AU5776799A (en) * 1998-08-21 2000-03-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modified hcv peptide vaccines
AU774076C (en) * 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
DZ3332A1 (fr) * 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
JP2003064096A (ja) 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc C型肝炎ウイルス特異的細胞障害性t細胞認識エピトープ

Similar Documents

Publication Publication Date Title
JP2010534684A5 (enExample)
JP2006527780A5 (enExample)
JP2011527560A5 (enExample)
JP2010501534A5 (enExample)
WO2009022236A8 (en) Immunogen platform
JP2009504138A5 (enExample)
JP2013509879A5 (enExample)
JP2011508438A5 (enExample)
JP2010273685A5 (enExample)
ATE551314T1 (de) Gasphasensynthese von 2,3,3,3-tetrafluor-1-propen aus 2-chlor-3,3,3-trifluor-1-propen
JP2009542225A5 (enExample)
JP2010141309A5 (ja) 発光素子
IL183165A0 (en) Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis
ZA200907242B (en) Nucleic acids
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
JP2009501689A5 (enExample)
JP2007523200A5 (enExample)
JP2007530049A5 (enExample)
WO2007027742A3 (en) SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
WO2005063787A3 (en) Propargyl substituted nucleoside compounds and methods
JP2006514072A5 (enExample)
NO20052392L (no) Fremgangsmate for fremstilling av acetylenforbindelser.
WO2004009633A8 (en) Serotonin receptor
JP2007277223A5 (enExample)
JP2008519854A5 (enExample)